GET DAILY SIGNALSWhy Is HeartBeam (BEAT) Stock Up +23.90% Today?
Key Takeaways
- Shares of BEAT rallied roughly 23.90% intraday, rising from a prior close of $0.4004 to about $0.4961.
- The primary catalyst was the company's announcement that results from its ALIGN-ACS pilot study will be presented at the TCT 2026 cardiology conference on November 1.
- Secondary drivers include the FDA's Breakthrough Device Designation and acceptance into the FDA's Total Product Life Cycle Advisory Program (TAP) awarded earlier this month.
- The move reflects sustained momentum behind HeartBeam's heart-attack assessment program rather than a single earnings or ratings event.
- Traders are watching the upcoming TCT 2026 data presentation and updates on the company's pivotal study timeline.
- For more detail on Price Targets, Earnings, and Forecast, explore these dedicated pages.
- Discover how AI-powered strategies are tracking this and other tickers on Trending AI Robots.
Opening Summary
HeartBeam, Inc. (BEAT), a medical technology company developing cable-free 3D ECG solutions for cardiac monitoring, saw its stock surge on Wednesday. The shares climbed approximately 23.90% intraday to around $0.4961, up from a prior-session close of $0.4004. The sharp upward move extended a period of elevated volatility tied to a series of regulatory and clinical milestones for the company's heart-attack assessment technology.
ALIGN-ACS Data Presentation Announced for TCT 2026
The most immediate catalyst was HeartBeam's announcement that results from its ALIGN-ACS pilot study will be presented at the TCT 2026 conference, held in San Diego from October 31 to November 3. The abstract, scheduled for Sunday, November 1, covers detection of acute coronary syndrome using the company's credit-card-sized three-lead device versus a standard 12-lead ECG in emergency department patients.
The pilot study enrolled 132 patients presenting with chest pain across two clinical sites in Belgrade, Serbia. Investors responded to the prospect of new clinical validation for the HeartBeam System, which the company views as a key step toward designing a U.S. pivotal study.
Regulatory Momentum: Breakthrough Designation and TAP Acceptance
The rally also reflects the accumulation of favorable FDA developments in recent weeks. Earlier this month, the FDA granted BEAT Breakthrough Device Designation for its 3D ECG technology as a tool for assessing potential heart attacks outside a medical setting. The agency acted within 30 days, well ahead of its 60-day statutory window.
Shortly afterward, the company announced acceptance into the FDA's Total Product Life Cycle Advisory Program (TAP) Pilot, which assigns dedicated FDA advisors and provides early engagement with payers, including the Centers for Medicare & Medicaid Services. Together, these milestones give HeartBeam a more predictable regulatory pathway and could position the device for accelerated reimbursement discussions.
Clinical Pipeline Progress Supports Sentiment
Broader clinical momentum has reinforced the bullish narrative. HeartBeam recently completed enrollment ahead of schedule in its HEADSTART-ACS study, a 486-patient heart attack detection trial conducted in collaboration with Indonesia's National Cardiovascular Center. The company has also joined a European research consortium to lead the HEART-CHECK study evaluating at-home ECG monitoring. These developments underscore management's strategic focus on heart attack assessment, which the company estimates as a roughly $15 billion market opportunity.
Market Context and Trading Activity
The move in BEAT reflects stock-specific, news-driven momentum rather than broad index movement. As a small-cap, development-stage medical device company, HeartBeam shares tend to be highly sensitive to regulatory and clinical headlines, and trading activity has been notably heavy across the recent FDA announcements. The stock remains well below its levels from earlier in the year, highlighting the volatility that typically accompanies early-stage medtech names awaiting pivotal data.
What Comes Next for BEAT
Looking ahead, the key near-term event is the ALIGN-ACS presentation at TCT 2026 on November 1, which could shape the design of HeartBeam's planned multicenter pivotal study. Management has said it anticipates seeking FDA alignment on the study design in the coming months and beginning patient enrollment in the first quarter of 2027. Risks remain substantial: the heart-attack indication is still investigational, and regulatory designations do not guarantee eventual clearance or reimbursement. Investors will also be watching for updates on the company's cash position, given its recent at-the-market equity offering and ongoing development-stage operating losses.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore automated approaches tailored to different market environments. To see which AI strategies are currently gaining traction, visit the Trending AI Robots page and explore the available options.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BEAT in +10.97% Uptrend, advancing for three consecutive days on October 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BEAT advanced for three days, in 169 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 71 cases where BEAT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for BEAT moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 22 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BEAT as a result. In 80 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for BEAT turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 39 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
BEAT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BEAT crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
BEAT broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BEAT entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.759) is normal, around the industry mean (4.353). P/E Ratio (-0.785) is within average values for comparable stocks, (13.253). Projected Growth (PEG Ratio) (0.290) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. BEAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a wireless medical technology company, which focuses on the delivery of health information
Industry ServicestotheHealthIndustry
Advertisement